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Background. The adequacy of the World Health Organization’s Integrated Management of Childhood Illness (IMCI) antimi-
crobial guidelines for the treatment of suspected severe bacterial infections is dependent on a low prevalence of antimicrobial resis-
tance (AMR). We describe trends in etiologies and susceptibility patterns of bloodstream infections (BSI) in hospitalized children 
in Malawi.
Methods. We determined the change in the population-based incidence of BSI in children admitted to Queen Elizabeth Central 
Hospital, Blantyre, Malawi (1998–2017). AMR profiles were assessed by the disc diffusion method, and trends over time were 
evaluated.
Results. A total 89 643 pediatric blood cultures were performed, and 10 621 pathogens were included in the analysis. Estimated 
minimum incidence rates of BSI for those ≤5 years of age fell from a peak of 11.4 per 1000 persons in 2002 to 3.4 per 1000 persons 
in 2017. Over 2 decades, the resistance of Gram-negative pathogens to all empiric, first-line antimicrobials (ampicillin/penicillin, 
gentamicin, ceftriaxone) among children ≤5 years increased from 3.4% to 30.2% (P <  .001). Among those ≤60 days, AMR to all 
first-line antimicrobials increased from 7.0% to 67.7% (P < .001). Among children ≤5 years, Klebsiella spp. resistance to all first-line 
antimicrobial regimens increased from 5.9% to 93.7% (P < .001).
Conclusions. The incidence of BSI among hospitalized children has decreased substantially over the last 20 years, although gains 
have been offset by increases in Gram-negative pathogens’ resistance to all empiric first-line antimicrobials. There is an urgent need to 
address the broader challenge of adapting IMCI guidelines to the local setting in the face of rapidly-expanding AMR in childhood BSI.
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Sepsis accounted for half a million child deaths globally in 2000, 
and had the lowest decline of all the top 7 causes of death in 
this population by 2015, with only a 25% decrease compared to 
other leading causes, such as pneumonia (47%), diarrhea (57%) 
and measles (85%) [1]. In 2015, sepsis and other infectious con-
ditions of the newborn accounted for 7% of all deaths world-
wide among children under 5 years of age [1]. Empiric, first-line 
antimicrobial treatment for sick infants in the World Health 
Organization’s (WHO’s) Integrated Management of Childhood 
Illness (IMCI) guidelines consists of penicillin/ampicillin with 
gentamicin, or ceftriaxone (as is practiced in Malawi). At our 
center in Malawi, ceftriaxone has been available since 2001, was 
introduced as an empiric antibiotic for neonatal meningitis in 
2009 [2], and has been used as the first-line treatment for sus-
pected neonatal sepsis since 2013 [3]. Pediatric departmental 
guidelines recommend the use of penicillin and gentamicin for 
suspected sepsis or ceftriaxone for suspected meningitis, typhoid 
fever, and non-typhoidal Salmonella (NTS). These recommen-
dations are based on sparse data from low- and middle-income 
countries (LMICs), and are intended to be adjusted to local sus-
ceptibility patterns so that “appropriate therapy [can be given] 
for an identified bacterial cause” [4]. This can be challenging in 
LMICs, where a paucity of diagnostic microbiology facilities [5] 
limits the ability of clinicians to optimize empiric therapy.
Child mortality in Malawi has been falling in the last 20 years 
as a consequence of multiple interventions, including bet-
ter nutrition, new vaccines (including the H.  influenzae type 
B conjugate vaccine in 2002 and S.  pneumoniae conjugate 
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vaccine in 2011), rapid roll-out of human immunodeficiency 
virus prevention and care, and improvements in malaria con-
trol [6–11]. A  growing problem has been increasing rates of 
antimicrobial resistance (AMR) [12, 13], which may be caused 
and compounded by inappropriate prescribing, under-dosing, 
and nonadherence to guidelines [14, 15]. There is a scarcity 
of high-quality bloodstream-infection (BSI) surveillance data 
to inform policy change. We have previously documented the 
expansion of extended-spectrum beta-lactamase (ESBL) and 
fluoroquinolone resistance among common Gram-negative 
pathogens, as well as the emergence of methicillin-resistant 
Staphylococcus aureus in BSI [12], but did not explore this in 
detail in the population ≤5  years, where the impact may be 
greatest. This study reviews the pediatric surveillance data col-
lected over 2 decades at an urban district hospital and tertiary 
referral center in Malawi. We describe trends in the etiology 
and the prevalence of AMR amongst BSI isolates cultured from 
hospitalized children. Finally, we assess the adequacy of current 
IMCI guidelines in this setting.
METHODS
Setting
Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi, is a 1250-bed, government-funded teaching hospital 
providing free medical care, and is the main teaching hospi-
tal of the University of Malawi College of Medicine. It is the 
referral center for the southern half of the country and serves 
as the district hospital for the urban Blantyre area (estimated 
population 920 000 in 2016). The pediatric department admits 
20 000–30 000 children a year, with 65 000–80 000 seen annually 
in the pediatric Accident and Emergency unit. Total numbers of 
pediatric hospital admissions have remained broadly constant 
over the study period (Supplementary Table 1). Similarly, the 
neonatal unit admits 3500 neonates a year, and these numbers 
have remained consistent over the past decade, since admission 
data were first collected.
Study Design
We reviewed blood culture data collected at QECH over 20 
consecutive years (1998–2017; Supplementary Figure 1). Blood 
culture sampling in children was obtained from any pediatric 
patient with a clinical suspicion of sepsis, severe sepsis, or septic 
shock [16]; with a non-focal febrile illness and a negative test 
for malaria; or who remained febrile despite empiric antimicro-
bial treatment. Sampling followed set departmental guidelines, 
which have remained unchanged over the period of surveil-
lance. Repeat blood cultures were not routinely done in the set-
ting of a positive result. Precise individual- or population-based 
antimicrobial usage data for the surveillance period were not 
available. An analysis of microbiological surveillance data was 
approved by the University of Malawi College of Medicine 
Research Ethics Committee (P.08/14/1614).
Microbiology
Routine, quality-assured, diagnostic blood culture services have 
been provided for children admitted to QECH by the Malawi-
Liverpool-Wellcome Trust Clinical Research Programme since 
1998. Among children, 1–2 mLs of blood were obtained, where pos-
sible, for culture under aseptic conditions and were inoculated into 
a single aerobic bottle (BacT/Alert, bioMérieux, Marcy-L’Etoile, 
France). All lab data over the study period were collected for chil-
dren ≤5 years, including young infants <60 days. Further clinical 
data was unavailable. Where possible, all duplicates were removed.
The automated BacT/Alert system (bioMérieux, France) has 
been used to incubate samples since 2000. Before then, manual 
cultures were used, as previously described [17], with organ-
ism identification using Analytical Profile Index (Biomérieux). 
Staphylococci were identified by slide coagulase, beta-hemo-
lytic Streptococci by Lancefield antigen testing, and Salmonellae 
by serotyping, according to the White-Kauffmann-Le Minor 
scheme. Haemophilus influenzae were typed using type B anti-
sera. Aerococcus spp., Alcaligenes spp., alpha-hemolytic strepto-
cocci (other than S. pneumoniae), Bacillus spp., Corynebacteria, 
Micrococcus spp., coagulase-negative staphylococci, unidenti-
fied gram-positive rods, and the Rhizobium spp. that form part 
of the normal skin or oral flora were considered contaminants.
In Malawi, first-line antimicrobial regimens for the treat-
ment of pediatric and neonatal BSI include ampicillin/penicil-
lin with gentamicin, or ceftriaxone. Antimicrobial susceptibility 
was determined by the disc diffusion method (Oxoid, United 
Kingdom), following the current version of the British Society 
of Antimicrobial Chemotherapy’s guidelines (http://www.
bsac.org.uk). Intermediate susceptibility (with the exception 
of S. pneumoniae) was regarded as resistant. Methicillin resis-
tance in S. aureus was inferred by resistance to cefoxitin, which 
replaced oxacillin resistance testing in 2010. For S. pneumoniae, 
reduced susceptibility to penicillin was detected by oxacillin 
disc, with resistance defined as a minimum inhibitory concen-
tration >2 µg/mL. Formal minimum inhibitory concentration 
testing was not done. Since 2007, gram-negative isolates have 
been screened for their ESBL-producing status using a cef-
podoxime disc. Prior to this, the ESBL-producing status was 
inferred based on any resistance to ceftriaxone.
Statistical Analysis
We estimated minimum annual incidence rates, expressed as inci-
dences per 1000 age-specific person years, by dividing the number of 
bacteremia cases per year by the mid-year population and multiply-
ing by 1000. We modeled the observed annual case frequencies and 
then estimated incidences by dividing the predicted case frequencies 
by the mid-year populations. Age-stratified population estimates for 
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urban Blantyre for the years 1998–2017 were obtained from the 1998 
and 2008 National Population Projections by the National Statistical 
Office (http://www.nsomalawi.mw). We used yearly values for chil-
dren ≤5 years, but when there were low numbers of cases, including 
for young infants ≤60 days, we combined data into 5-year periods 
to enable comparisons. We followed the WHO definition of young 
infants as ≤60  days [4] and defined early-onset neonatal BSI as 
<7 days and late-onset neonatal BSI as 7–90 days. We used negative, 
binomial regression models to test for linear trends in incidence rates 
and the Cochran-Armitage test to detect trends in AMR rates. All 
statistical analyses were performed using R Statistical Package ver-
sion 3.3.2 for MacOS (R Core Team, http://www.r-project.org).
RESULTS
Between 1998–2017, a total of 89 643 blood cultures from pedi-
atric patients were identified. Of these, 10 621 pathogenic bacte-
ria were identified from children ≤5 years, including 2898 from 
young infants ≤60 days.
Incidence Rates
Minimum incidence rates of pediatric BSI decreased signifi-
cantly over 2 decades (Figure  1), falling from a peak of 11.4 
per 1000 persons in 2002 for children ≤5  years to 3.4 per 
1000 persons in 2017 (overall decreasing trend, P  <  .001). 
For young infants, minimum incidence rates decreased from 
8.7 per 1000 persons in 2000 to 1.7 per 1000 persons in 2008 
(P =  .05). However, since 2008, minimum incidence rates for 
young infants have been rising, with a steep rise from 2.8 per 
1000 persons in 2015 to 6.3 per 1000 persons in 2017. For most 
pathogens, there is an overall decreasing trend in minimum 
incidence rates (Figure 1) over these 2 decades, with the excep-
tion of Salmonella Typhi and Klebsiella spp. For S. Typhi, min-
imum incidence rates for children ≤5  years increased from a 
low of 0 per 1000 persons in 2003 to a peak of 1.3 per 1000 per-
sons in 2013, and then declined to 0.3 per 1000 persons in 2017 
(overall increasing trend, P =  .0016); for Klebsiella spp., mini-
mum incidence rates went from a low of 0.2 per 1000 persons in 
2012 to 0.9 per 1000 persons in 2017 (P = .727). However, when 
Figure 1. Negative binomial regression model–estimated annual incidence rate per 1000 person-years for children ≤5 years, for: (A) all pathogenic organisms among those 
≤5 years and ≤60 days; (B) S. pneumoniae and S. aureus; (C) GAS and GBS; (D) S. Typhi and NTS; (E) E. coli and Klebsiella spp.; and (F) Haemophilus spp. and other Gram-
negatives. Scales have been adjusted for each organism. Abbreviations: CI, confidence interval; GAS, Group A Strep; GBS, Group B Strep; NTS, non-typhoidal Salmonella.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy834/5113431 by U
niversity C
ollege London user on 03 January 2019
4 • CID 2018:XX (XX XXXX) • Iroh Tam et al
the outlier values for 2016 and 2017 were excluded, there was a 
declining trend for Klebsiella spp. sepsis between 1998 and 2015 
(P = .009).
Pathogen Etiology
During the first period (1998–2002; Table 1), NTS accounted for 
41.4% (1644/3964) of pathogenic isolates, followed by S. pneu-
moniae at 10.2% (405/3964) and S. aureus and E. coli at 6.2% 
each (247/3964). In the last period (2013–2017), the most com-
mon causes of pediatric BSI were Salmonella Typhi (544/2614, 
20.8%), Klebsiella spp. (316/2614, 12.1%, with K.  pneumoniae 
comprising 93.7% [295] of these), NTS (303/2614, 11.6%), 
and Staphylococcus aureus (253/2614, 9.7%). S.  pneumoniae 
accounted for 1.9% (49/2614) of isolates in the last period. For 
young-infant BSI in the first period (Supplementary Table 2), 
the most common causes were NTS (133/835, 15.9%), S. aureus 
(118/835, 14.1%), and Group B Strep (109/835, 13.1%). In 
the last period, the most common causes were Klebsiella spp. 
(230/800, 28.9%), followed by S.  aureus (139/800, 17.4%), 
Enterobacter spp. (101/800, 12.6%), Enterococcus spp. (72/800, 
Table 1. Bloodstream Infections in Children ≤5 Years at Queen Elizabeth Central Hospital, by Isolate and Period
Time Period
1998–2002 2003–2007 2008–2012 2013–2017
n % n % n % n %
Gram-positives
 Group A Strep 96 2.4 42 1.1 32 1.7 29 1.1
 Group B Strep 126 3.2 116 2.9 39 2.0 48 1.8
 Streptococcus pneumoniae 405 10.2 423 10.7 166 8.6 49 1.9
 Staphylococcus aureus 247 6.2 283 7.1 185 9.6 253 9.7
 Other Streptococcus spp. 197 5.0 244 6.1 193 10.0 222 8.5
 E. faecalis 26 0.7 63 1.6 38 2.0 30 1.1
 E. faecium 0 0 0 0 10 0.5 69 2.6
 All Enterococcus spp. 31 0.8 63 1.6 50 2.6 99 3.8
 Leuconostoc 0 0 1 0.03 0 0 0 0
Gram-negatives
 Acinetobacter baumanii 0 0 9 0.2 17 0.9 58 2.2
 All Acinetobacter spp. 86 2.2 101 2.5 35 1.8 59 2.3
 Citrobacter spp. 37 0.9 33 0.8 6 0.3 7 0.3
 Enterobacter spp. 57 1.4 133 3.4 33 1.7 132 5.0
 Escherichia coli 247 6.2 282 7.1 163 8.5 165 6.3
 Haemophilus influenzae type B 157 4.0 44 1.1 19 1.0 16 0.6
 All Haemophilus spp. 178 4.5 67 1.7 38 2.0 26 1.0
 Klebsiella pneumoniae 57 1.4 103 2.6 123 6.4 295 11.3
 All Klebsiella spp. 179 4.5 144 3.6 132 6.9 316 12.1
 Neisseria meningitidis 14 0.3 18 0.5 5 0.3 11 0.4
 N. gonorrhoea 0 0 0 0 1 0.05 6 0.3
 Proteus spp. 15 0.4 3 0.08 2 0.1 3 0.1
 Pseudomonas aeruginosa 28 0.7 47 1.2 20 1.0 36 1.4
 All Pseudomonas spp. 38 1.0 55 1.4 33 1.7 49 1.9
 Salmonella typhi 8 0.2 16 0.4 50 2.6 544 20.8
 NTS 1644 41.4 1505 37.9 532 27.7 303 11.6
 Serratia spp. 38 1.0 16 0.4 4 0.2 17 0.7
 Shigella spp. 3 0.08 4 0.1 4 0.2 6 0.2
 Vibrio spp. 0 0 0 0 2 0.1 0 0
 Yersinia spp. 2 0.05 0 0 2 0.1 0 0
 Other Gram-negativesa 301 7.6 412 10.4 203 10.6 253 9.7
Fungus
 Candida 5 0.1 1 0.03 4 0.2 7 0.3
 Cryptococcus 0 0 0 0 6 0.3 4 0.2
 Yeast species 0 0 0 0 0 0 3 0.1
 All pathogensb 3964 100 3970 100 1923 100 2614 100
Abbreviation: NTS, non-typhoidal Salmonella.
aIncludes Aeromonas spp., Agrobacter spp., Burkholderia spp., Cronobacter spp., Edwardsiella spp., Flavobacteria, Gram-negative rods, Hafnia spp., Histophilus spp., Kluyvera spp., 
Moraxella spp., Morganella spp., Pantoea spp., Pasteurella spp., Raoultella spp., Sphingomonas spp., Stenotrophomonas spp., and Xanthomonas spp.
bExcludes contaminants, including Aerococcus spp., alpha-hemolytic streptococci, Alcaligenes spp., Bacillus spp., Clostridium spp., coagulase-negative staphylococci, Corynebacteria, 
Diphtheroids, Gram-positive rods, Rhizobium spp., Micrococcus spp., and skin flora.
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9%), E. coli (57/800, 7.1%), and Group B Strep (43/800, 5.4%). 
Only 0.6% (5/800) of S.  pneumoniae specimens were iso-
lated from young infants in the last period, compared to 6.2% 
(52/835) in the first.
Antimicrobial Resistance Profiles
For Gram-positive pathogens, resistance to empiric, first-line 
antimicrobials—ampicillin/penicillin with gentamicin, or cef-
triaxone—was 21.1% (605/2863) and 6.2% (74/1199) of isolates, 
respectively. For Gram-negative pathogens, the proportion of 
culture-confirmed BSI among children ≤5 years that were resis-
tant to all first-line antimicrobials had an overall increasing 
trend over time, from 3.4% (8/235) in the first period to 30.2% 
(449/1487) in the last period (P  <  .001; Figure  2). For young 
infants, the overall proportion of Gram-negative bacteria resis-
tant to all first-line antimicrobials increased from 7.0% (3/43) 
in the first period to 67.7% (315/465) in the last (P < .001).
For Gram-positive pathogens, penicillin resistance (includ-
ing intermediate susceptibility) in S.  pneumoniae did not 
increase significantly during the study period (P = .210; Table 2). 
Methicillin-resistant Staphylococcus aureus isolates increased 
from 0% (0/247) to 2.7% (6/224), which was not significant 
(P  =  .09). Enterococcus spp. resistance to ampicillin increased 
from 11.1% (1/9) in the first period to 69.7% (69/99) in the last 
(P < .001), which could be attributed to the 7-fold increase in 
E. faecium spp. isolated, concurrent with a relative decrease in 
E. faecalis over the same period.
For Gram-negative pathogens, excluding Salmonellae, an 
increase in resistance to ceftriaxone and gentamicin to over 
60% during the study period was documented (Figure  3). 
E.  coli’s resistance to ceftriaxone increased from 11.1% (4/36) 
in the first period to 28.5% (47/165) in the last (P < .001), while 
its resistance to gentamicin increased from 19.7% (48/244) in 
the first period to 32.7% (54/165) in the last (P < .001), and its 
resistance to ampicillin remained unchanged and had a mean 
annual rate of 89.7% throughout the study period (P =  .466). 
For Klebsiella spp., ceftriaxone resistance rose from 21.1% 
(4/19) in the first period to 90.5% (286/316) in the last (overall 
increasing trend, P < .001), whereas gentamicin resistance rose 
from 38.2% (68/178) in the first period to 90.7% (282/311) in 
the last (overall increasing trend, P <  .001). Resistance to cip-
rofloxacin for both pathogens was also observed to steadily 
increase during the entire 2 decades, from 0% (0/113) in the 
first period to 26.0% (43/165) in the last (P < .001) in E. coli and 
from 0% (0/73) to 34.5% (109/316) for Klebsiella spp (P < .001). 
Resistance to all empiric, first-line antimicrobials for E. coli was 
over 20% (Figure 3) and there was an overall increasing trend in 
the proportion of Klebsiella spp. resistant to all first-line antimi-
crobial regimens over time, from 5.9% (1/17) to 93.7% (133/142; 
P < .001). Both S. Typhi and NTS had infrequent resistances to 
ceftriaxone (0/566 and 8/1980) and ciprofloxacin (1/610 and 
10/3392) throughout all periods. We have not detected ESBL 
NTS BSI in children [18]. A similar trend in AMR profiles was 
also noted for young infants (Supplementary Table 3).
DISCUSSION
Over the past 2 decades, overall, the incidence of BSI in hos-
pitalized children at QECH, the largest teaching hospital in 
Malawi, has decreased. This includes NTS, for which no vaccine 
was available during the study period, and H. influenzae type B 
and S. pneumoniae, for which vaccination programs were intro-
duced during the study period (in 2002 and 2011, respectively). 
However, in the last 10  years, the incidence of young infant 
BSI caused by S. Typhi and Klebsiella spp. in those under 5 has 
risen considerably. We have previously reported 3 epidemics of 
Salmonella, which appear to have arisen through the acquisition 
of virulence and AMR determinants in the context of a suscepti-
ble population [19–22]. Gram-positive pathogens are still largely 
susceptible to first-line antimicrobials, with the exception of 
Enterococcus spp. and E. faecium, which, as an emerging patho-
gen, needs ongoing surveillance. For Gram-negative BSI among 
children ≤5 years, the proportion of bacteria that are resistant to 
empiric, first-line antimicrobials is high, rising, and most marked 
among young infants. These findings reveal the growing problem 
of AMR in our setting and emphasize the need for robust anti-
microbial stewardship programs and ongoing surveillance, even 
when BSI overall appears to be declining.
The rise in the number of Gram-negative pathogens resis-
tant to first-line antimicrobials, specifically Klebsiella spp., 
contrasts with earlier data from our institution, where isolates 
had high susceptibility (78%) [23]. One reason for the rise in 
Figure  2. Proportion of culture-confirmed bloodstream pathogens resistant 
to empiric first-line antimicrobials by period, for children ≤5 years and ≤60 days. 
First-line antimicrobials in Malawi are ampicillin/penicillin with gentamicin, or 
ceftriaxone.
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Table 2. Antimicrobial Resistance Profiles of Selected Bloodstream Pathogens for Children ≤5 Years, by Period
Pathogen Time Period
Antimicrobial Resistance
Ampicillin Penicillin Ceftriaxone Chloramphenicol Gentamicin Co-trimoxazole Ciprofloxacin
n % n % n % n % n % n % n %
S. pneumoniae 1998–2002 NT 91/ 374 24.3 0a/ 50 0 56/ 374 15.0 NT 314/ 364 82.3 NT
2003–2007 NT 73/ 420 17.4 0a/ 421 0 72/ 418 17.2 NT 387/ 411 94.2 NT
2008–2012 NT 29/ 164 17.7 0a/ 166 0 21/ 164 17.7 NT 153/ 166 92.3 NT
2013–2017 NT 15/ 49 30.6 0a/ 48 0 15/ 49 30.6 NT 46/49 93.9 NT
S. aureusb 1998–2002 NT 227/ 245 92.7 NT 97/ 241 40.2 27c/ 236 11.4 127/ 244 52.0 NT
2003–2007 NT 245/ 262 93.5 NT 85/ 269 31.6 28c/ 222 12.6 137/ 265 51.7 NT
2008–2012 NT 47/ 57 82.5 NT 29/ 181 16.0 20c/ 160 12.5 78/ 180 43.3 NT
2013–2017 NT NT NT 12/ 253 4.7 20c/ 224 8.9 96/ 253 37.9 NT
Enterococcus spp. 1998–2002 1/ 9 11.1 16/ 27 59.3 NT 14/ 30 46.7 20/ 22 90.9 17/ 31 54.8 NT
2003–2007 5/ 44 11.4 28/ 32 87.5 NT 38/ 62 61.3 8/ 8 100 33/ 61 54.1 NT
2008–2012 17/ 38 44.7 2/ 2 100 NT 33/ 47 70.2 2/ 3 66.7 40/ 44 90.9 NT
2013–2017 69/ 99 69.7 NT NT 74/ 98 75.5 1/ 1 100 73/ 98 74.5 NT
E. coli 1998–2002 222/ 246 90.2 NT 4/ 36 11.1 172/ 243 70.8 48/ 244 19.7 213/ 242 88.0 0/ 113 0
2003–2007 237/ 272 87.1 NT 14/ 237 5.9 178/ 277 64.3 74/ 274 27.0 244/ 271 90.0 9/ 275 3.3
2008–2012 147/ 162 90.7 NT 24/ 154 15.6 99/ 162 61.1 57/ 161 35.4 150/ 162 92.6 23/ 161 14.3
2013–2017 147/ 163 90.2 NT 47/ 165 28.5 72/ 165 43.6 54/ 165 32.7 160/ 165 97.0 43/ 165 26.0
Klebsiella spp. 1998–2002 178/ 178 100 NT 4/ 19 21.1 139/ 177 78.5 68/ 178 38.2 149/ 176 84.7 0/ 73 0
2003–2007 136/ 140 97.1 NT 18/ 123 14.6 98/ 139 70.5 72/ 144 50 109/ 140 77.9 11/ 142 7.7
2008–2012 130/ 131 99.2 NT 90/ 118 76.3 85/ 129 65.9 105/ 130 80.8 116/ 131 88.5 26/ 131 19.8
2013–2017 316/ 316 100 NT 286/ 316 90.5 167/ 315 53.0 282/ 311 90.7 299/ 315 94.9 109/ 316 34.5
Enterobacter spp. 1998–2002 48/ 53 90.6 NT 100d 34/ 57 59.6 19/ 55 34.5 36/ 56 64.3 1/ 40 2.5
2003–2007 95/ 122 77.9 NT 100d 70/ 131 53.4 33/ 114 28.9 79/ 131 60.3 7/ 119 5.9
2008–2012 29/ 31 93.5 NT 100d 22/ 32 68.8 21/ 32 65.6 27/ 32 84.4 18/ 32 56.3
2013–2017 126/132 95.5 NT 100d 120/ 132 90.9 101/ 132 76.5 115/ 132 87.1 87/ 132 65.9
Acinetobacter spp. 1998–2002 55/ 83 66.3 NT 3/ 12 25 54/ 84 64.3 30/ 84 35.7 57/ 85 67.1 2/ 38 5.3
2003–2007 70/ 95 73.7 NT 45/ 95 47.4 82/ 100 82 43/ 101 42.6 85/ 98 86.7 26/ 101 25.7
2008–2012 25/ 32 78.1 NT 21/ 31 67.7 30/ 34 88.2 16/ 33 48.5 27/ 35 77.1 9/ 33 27.3
2013–2017 45/ 59 76.3 NT 57/ 59 96.6 52 /59 88.1 26/ 59 44.1 40/ 59 67.8 27/ 59 45.8
Pseudomonas spp. 1998–2002 NTd NT NT NTe 6/ 38 15.8 NTd 0/ 24 0
2003–2007 NTd NT NT NTe 20/ 55 36.4 NTd 2/ 55 3.6
2008–2012 NTd NT NT NTe 8/ 31 25.8 NTd 5/ 31 16.1
2013–2017 NTd NT NT NTe 12/ 49 24.5 NTd 8/ 49 16.3
Salmonella Typhi 1998–2002 4/ 7 57.1 NT 0/ 2 0 3/ 7 42.9 100f 4/ 7 57.1 0/ 1 0
2003–2007 2/ 16 12.5 NT 0/ 16 0 0/ 16 0 100f 0/ 16 0 0/ 15 0
2008–2012 37/ 50 74 NT 0/ 50 0 37/ 50 74 100f 35/ 50 70 1/ 50 2
2013–2017 532/ 544 97.8 NT 0/ 498 0 526/ 544 96.7 100f 533/ 544 98.0 0/ 544 0
NTS 1998–2002 1481/ 1603 92.4 NT 0/ 41 0 904/ 1609 56.1 100f 1430/ 1604 89.2 1/ 1070 0.1
2003–2007 1382/ 1488 92.9 NT 3/ 1142 0.3 1297/ 1497 86.6 100f 1317/ 1437 91.6 9/ 1495 0.6
2008–2012 459/ 527 87.1 NT 2/ 495 0.4 415/ 526 78.9 100f 456/ 528 86.4 0/ 524 0
2013–2017 241/ 303 79.5 NT 3/ 302 1.0 177/ 303 58.4 100f 238/ 303 78.5 0/ 303 0
Other Entero- 
bacteriaceaeg
1998–2002 94/ 102 92.2 NT 1/ 2 50 82/ 104 78.8 26/ 105 24.8 82/ 105 78.1 1/ 70 1.4
2003–2007 59/ 69 85.5 NT 6/ 55 10.9 43/ 69 42.0 16/ 70 22.9 37/ 62 59.7 8/ 69 11.6
2008–2012 16/ 24 66.7 NT 4/ 20 20 8/ 24 33.3 6/ 21 28.6 15/ 24 62.5 5/ 23 21.7
2013–2017 33/ 42 78.6 NT 18/ 42 42.9 19/ 42 45.2 13/ 41 31.7 29/ 41 70.7 12/ 42 28.6
Other Gram- 
negativesh
1998–2002 105/ 145 72.4 0/ 12 0 4/ 123 3.3 75/ 161 46.6 11/ 159 6.9 141/ 158 89.2 1/ 12 8.3
2003–2007 54/ 93 58.1 4/ 23 17.4 4/ 121 0.3 64/ 122 52.5 21/ 118 17.8 85/ 109 78.0 5/ 77 6.5
2008–2012 52/ 76 68.4 5/ 7 71.4 18/ 109 16.5 42/ 84 50 31/ 108 28.7 64/ 86 74.4 17/ 70 24.3
2013–2017 44/ 52 84.6 4/ 9 44.4 25/ 75 33.3 31/ 63 49.2 23/ 57 40.4 38/ 50 76 10/ 50 20
Abbreviations: NT, not tested; NTS, nontyphoidal Salmonella.
aPneumococcal isolates initially reported as ceftriaxone-resistant were re-tested and found to be susceptible. Based on these, isolates not available for re-testing (9) were considered susceptible.
bMethicillin-resistant Staphylococcus aureus isolates for these periods were: 1998–2002, 0 (0%); 2003–2007, 12 (0.3%); 2008–2012, 20 (1.0%); and 2013–2017, 35 (1.3%).
cNote that gentamicin should not be used alone for S. aureus, even if susceptible.
dAll Enterobacter isolates have been reported resistant to ceftriaxone, in line with British Society of Antimicrobial Chemotherapy (BSAC) guidance.
eAll Pseudomonas isolates have been reported not tested, as these pathogens are intrinsically resistant to ampicillin, chloramphenicol, and co-trimoxazole.
fAll Salmonella isolates have been reported resistant to gentamicin, in line with BSAC guidance.
gIncludes Citrobacter spp., Coliforms, Cronobacter spp., Escherichia spp., Hafnia spp., Kluyvera spp., Morganella spp., Pantoea spp., Proteus spp., Raoultella spp., Serratia spp., Shigella spp., and 
Yersinia spp.
hIncludes Aeromonas spp., Burkholderia spp., Edwardsiella spp., Flavobacteria, Gram-negative rods, Haemophilus spp., Histophilus spp., Moraxella spp., Neisseria spp., Pasteurella spp., 
Sphingomonas spp., Stenotrophomonas spp., Vibrio spp., and Xanthomonas spp.
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AMR could be attributed to a marked increase in the use of 
broad-spectrum antimicrobials in recent years [24], including 
among neonates. Klebsiella spp. isolates recovered within the 
first 3 days of birth accounted for 28.4% (84/295) of all pediat-
ric Klebsiella spp. specimens in the last period, suggesting high 
rates of vertical transmission. The reasons for increases in rates 
of AMR Klebsiella spp. are not certain, since there have been no 
changes in practices in the neonatal unit that we can identify. 
The increase may have been amplified by an increased trans-
mission capacity, resulting in outbreaks in neonatal units [25, 
26]. The high ESBL carriage in children <5 years [27] may have 
also contributed to horizontal transmission. Community-based 
surveillance of both the disease and carriage is ongoing [28] 
to explore whether increasing rates of AMR may be related to 
the strengthening of primary healthcare systems following the 
model of IMCI and earlier treatment with antimicrobials, and 
may thereby be limited to the hospital setting.
Alternative antimicrobials for Gram-negative pathogens in 
these settings could include the use of amikacin, where resis-
tance rates are much lower than gentamicin (6.3% compared to 
66.0%, respectively); or ciprofloxacin, where resistance rates are 
already rising, although, when used in children, this has to be 
weighed against the side effects of tendinopathy. The inclusion 
of meropenem on the Malawi national formulary in 2015 and 
its availability in hospitals may be beneficial in the short term, 
but increased use is likely to drive further AMR, similar to the 
increase in ESBL organisms seen following ceftriaxone use. This 
would be in a setting where there are limited diagnostic facili-
ties and where antimicrobial stewardship initiatives are beset by 
scarce resources.
Limitations to this study include that these are urban, tertiary, 
referral, hospital-based data from a single site, and not national 
surveillance. However, such large-scale, long-term, routine sur-
veillance data is rarely available in this setting at a national level. 
Hospital-based surveillance could have impacted the rates of 
AMR, as susceptible BSI may have responded to empiric oral 
antibiotics in the community, and only the sickest children 
present to the hospital. However, given the likely clinical severity 
of BSI, except for in children with typhoid fever, and the absence 
of other pediatric inpatient facilities, this bias is unlikely to be 
substantial. We could not reliably differentiate community- from 
hospital-acquired BSI, which could be particularly relevant to 
young-infant BSI, where some neonates have prolonged stays 
and have follow-up blood cultures obtained prior to changes 
in antimicrobial regimens for presumed sepsis. Nosocomial 
BSI may have contributed to our relatively high recovery rate of 
11.9%, but many of the prominent pathogens are uncommonly 
associated with nosocomial transmission. As blood cultures are 
not routinely repeated if the bacteria that are considered con-
taminants are isolated, we may have underestimated the number 
of true pathogens; however, typical risk factors, such as indwell-
ing vascular devices or febrile neutropenia, are extremely rare 
in this population and prematurity would not have accounted 
for a substantial proportion. ESBL screening was not intro-
duced until 2003; therefore, ESBL-producing pathogens may 
have been circulating yet undetected before then. Changes made 
to breakpoints in subsequent British Society of Antimicrobial 
Chemotherapy versions would have led to a wider use of “inter-
mediate” categories that, in our study, may have increased the 
number of Gram-negative pathogens regarded as resistant. In all 
pediatric BSI surveillance studies, the available blood volumes 
for culture remain a challenge and, therefore, underestimates of 
pathogens such as S. pneumoniae and S. Typhi are possible, par-
ticularly in infants. Comprehensive clinical data was not availa-
ble to evaluate the contribution of AMR to mortality; however, 
we have previously reported the mortality associated with spe-
cific pathogens [29–32].
Our results raise significant concerns about the growing issue 
of AMR, and highlight the urgent need to review empiric, anti-
microbial regimens; implement and enforce infection control 
practices; and undertake pragmatic trials of antimicrobial stew-
ardship. However, in many LMICs, without local data, it remains 
challenging to adapt the WHO IMCI guidelines to reflect local 
needs [5]. While awaiting both the impact of international 
Figure 3. Proportion of non-Salmonella, Gram-negative isolates with: (A) Gentamicin- or ceftriaxone-resistance, for children ≤5 years; or (B) E. coli and Klebsiella spp. 
resistance to empiric first-line antimicrobials, for children ≤5 years. First-line antimicrobials in Malawi are ampicillin/penicillin with gentamicin, or ceftriaxone.
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initiatives to expand access to high-quality laboratory surveil-
lance [33, 34] and the development of rapid diagnostics [35, 36], 
there should be a considerable emphasis on expanded access to 
effective antimicrobials in the context of locally-relevant anti-
microbial stewardship programs. These should include the edu-
cation of community- and hospital-based healthcare providers 
on prescribing practices, the epidemiology of infections, when 
not to prescribe antibiotics, the development of and adherence 
to guidelines on de-escalation and cessation of antimicrobial 
therapy, and infection control practices. The development of 
pragmatic clinical trials to evaluate new antimicrobial strategies 
in young children should be a priority.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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